Corporate
Alfasigma Completes Agreement with GSK for linerixibat
Alfasigma S.p.A., a global pharmaceutical company, today announced the completion of its previously announced licence agreement with GSK plc.
Pharmaceuticals
with passion
Corporate
Alfasigma Streamlines Manufacturing Footprint to Sharpen Strategic Focus and Accelerate Innovation and Growth
Alfasigma, a global pharmaceutical company headquartered in Italy, today announced that it has entered into an agreement for the sale of 100% of the share capital of its subsidiary Sofar S.p.A. (“Sofar”), which includes the production site in Trezzano Rosa, to Fine Foods & Pharmaceuticals N.T.M. S.p.A. (“Fine Foods”).
Corporate
Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%)[1], Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets.
Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fiscal year 2025. Its results reflect a year of strategic evolution and solid performance of key brands – all contributing to market share growth.
Therapeutic areas
Gastroenterology
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, IBD (Inflammatory Bowel Disease), gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis), Ulcerative Colitis, PBC (Primary Biliary Cholangitis)
Vascular
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies are the main pathologies in which we offer solutions
Rheumatology
We provide treatments to relieve symptoms and signs in patients affected by rheumatoid arthritis
Metabolic
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles
Nutraceuticals & Medical foods
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue
CSR
Alfasigma's business strategy is closely linked to the principles of sustainability. We support scientific popularization and play a proactive role in the areas of culture, art, and civil society. We recognize that a pharmaceutical company is also a cultural entity. The dignity of a person is not only about being healthy, but encompasses all aspects of life and the environment in which they live, reflecting an idea of the overall well-being of society.